Pathogenesis of intractable chronic lymphocytic leukemia (ICLL)

About 23% of all patients with chronic lymphocytic leukemia (CLL) are resistant to chemotherapy and have intractable CLL. Recent work showed the usefulness of splenectomy for the treatment of ICLL patients. The peripheral blood lymphocytes of ICLL patients were radioresistant in vitro. This reaction...

Full description

Saved in:
Bibliographic Details
Published inMedical hypotheses Vol. 30; no. 4; pp. 229 - 230
Main Author Schrek, R.
Format Journal Article
LanguageEnglish
Published United States Elsevier Ltd 01.12.1989
Subjects
Antineoplastic Agents - therapeutic use
Drug Resistance
Humans
Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell - etiology
Leukemia, Lymphocytic, Chronic, B-Cell - therapy
Lymphocytes - radiation effects
Models, Biological
Radiation Tolerance
Splenectomy
Online AccessGet full text

Cover

More Information
Summary:About 23% of all patients with chronic lymphocytic leukemia (CLL) are resistant to chemotherapy and have intractable CLL. Recent work showed the usefulness of splenectomy for the treatment of ICLL patients. The peripheral blood lymphocytes of ICLL patients were radioresistant in vitro. This reaction provided a diagnostic test for ICLL. Normal lymphocytes are highly radiosensitive but become radioresistant on the addition of phytohemagglutinin or other mitogens. These findings suggest the hypotheses: ICLL arises from splenic lymphocytes which have reacted to an immune stimulus; ICLL is a discrete disease with its own pathogenesis, diagnosis and therapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0306-9877
1532-2777
DOI:10.1016/0306-9877(89)90030-3